Compare Amphastar Pharmaceuticals Inc (AMPH) vs Five9 Inc (FIVN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Five9 Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Five9 Inc trades at $25.5 (market cap $1.95B). The key difference: Five9 Inc is far larger — about 2.4× Amphastar Pharmaceuticals Inc's market cap, and Five9 Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | FIVN | |
|---|---|---|
Market Cap | $826.08M | $1.95B |
Sector | Health | Technology |
52-Week High | $30.81 | $29.16 |
52-Week Low | $16.87 | $13.61 |
Enterprise Value | $1.22B | $2.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Five9 (FIVN) trades at $25.42, up 1.97% with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $779M in 2022 to $1.15B in 2025 and a shift to profitability. Recent Q1 2026 earnings beat expectations, and the stock benefits from strong analyst support (61% buy rating) and a $27 consensus price target. However, negative net cash flow and ongoing legal scrutiny present near-term headwinds.
The outlook remains positive given consistent earnings beats and strategic leadership appointments, but risks include insider selling and litigation concerns. Upside potential exists if the company maintains its growth trajectory and addresses cash flow challenges, making it a watch for growth-oriented investors despite volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →
